Is the Market Bullish or Bearish on Krystal Biotech?
According to Benzinga Pro, Krystal Biotech's peer group average for short interest as a percentage of float is 12.98%, which ...
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicinal ...
Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus
Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...
PMLive2d
Rare diseases: CHMP recommends Krystal’s Vyjuvek for dystrophic epidermolysis bullosa
The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...
The Pharma Letter1d
Russia plans to increase procurements of rare disease drugs
Russia plans to increase procurements of drugs against rare diseases despite the current tough business environment and ...
Brokers Issue Forecasts for Krystal Biotech FY2026 Earnings
Investment analysts at Chardan Capital issued their FY2026 EPS estimates for Krystal Biotech in a research note issued to ...
Krystal gets positive EU regulatory opinion for Vyjuvek
Krystal Biotech (KRYS) has received a positive recommendation from EU regulators for its drug Vyjuvek for the treatment of ...
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Krystal Biotech (KRYS) and Treace Medical Concepts (TMCI)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merus (MRUS – Research Report), Krystal Biotech ...